Case Report: Tislelizumab-induced panuveitis: a report of two cases.

Background: Tislelizumab, an increasingly utilized immunotherapy for a range of malignancies, can induce a rare ocular immune-related adverse event resembling Vogt-Koyanagi-Harada-like syndrome (VKHLS). Management of complication requires careful balancing with ongoing systemic anti-tumor therapy. Case Presentation: This report describes two cancer patients who developed severe bilateral vision loss following Tislelizumab treatment. Multimodal ocular imaging confirmed the diagnosis of immune checkpoint inhibitors (ICIs)-associated uveitis, specifically a VKHLS. Both patients were managed with discontinuation of Tislelizumab and local corticosteroid therapy-transcutaneous periocular injection of triamcinolone acetonide (TA) and topical steroid eye drops, without systemic corticosteroids. Their uveitis resolved rapidly, with recovery of visual acuity. Conclusion: Prompt Tislelizumab discontinuation combined with local corticosteroid therapy-transcutaneous periocular TA injections, and topical steroid eye drops may constitute an effective management strategy for ICIs-induced uveitis. This approach is particularly valuable for cancer patients in whom systemic corticosteroids are contraindicated or unsuitable.